



Subscribe to follow us @ILPMP on YouTube

View as Webpage

# **ILPMP Data Dashboards Overview Video**



# ILPMP State Level Dashboard Release 2023 Total Opioid Prescription and Patient Data

The ILPMP provides regularly updated de-identified data for public viewing. This allows Local Health Departments to analyze trends in their regions, enabling them to target geographical areas for healthcare provider education and outreach and assess the effectiveness of public health interventions.

The state level data dashboard - total opioid prescriptions and opioid patients - has been recently updated with 2023 data located on **ILPMP.org.** 

Click to View 2023 Total Opioid Prescriptions and Patients

## FDA Releases Narcan Shelf-Life Extension

At the request of US Food and Drug Administration (FDA), Emergent BioSolutions has extended the shelf-life for NARCAN 4 milligram (mg) Nasal Spray from 3-years to 4-years. This shelf-life extension applies only to NARCAN (4 mg) nasal spray products produced after January 18, 2024. The shelf-life of products that were produced and distributed prior to this date is not affected and remains unchanged.



# Over and Under Prescribing Opioids - An Article Reiterating the Importance of Continuous Education and Training when Prescribing Opioids

The **ILPMP Peer Review Committee**, internal team, had an opportunity to discuss this insightful article, *NP Safe Prescribing of Controlled Substances While Avoiding Drug Diversion*, in a group meeting. The purpose of the ILPMP Peer Review Committee is to identify those prescribers who may be prescribing outside the currently accepted standards of practice for their profession. (**720 ILCS 570/320**) An important takeaway from this article circled around the importance of education and training regarding over and under prescribing opioids for **best patient** *outcomes.* "All providers that prescribe opioids need additional education and training to provide the best patient outcomes and avoid the social and legal entanglements associated with over and under prescribing opioids."

"Unfortunately, there are numerous challenges in pain management, such as both under prescribing and overprescribing opioids. The concerns are particularly prominent in patients with chronic pain and have resulted in patients suffering from inadequately treated pain while at the same time there has been a development of concomitant opioid abuse, addiction, diversion, and overdose. As a result, providers are often negatively influenced and fail to deliver appropriate, effective, and safe opioids to patients with chronic pain. Providers have, in the past, been poorly trained and ill-informed in their opioid prescribing. To make the challenges even worse, chronic pain patients often develop opioid tolerance, significant psychological, behavioral, and emotional problems, including anxiety and depression related to under or overprescribing opioids.

There are substantial knowledge gaps around appropriate and inappropriate opioid prescribing, including deficits in understanding current research, legislation, and appropriate prescribing practices. Providers often have knowledge deficits that include:

- Understanding of addiction
- At-risk opioid addiction populations
- Prescription vs. non-prescription opioid addiction
- The belief that addiction and dependence on opioids is synonymous
- The belief that opioid addiction is a psychologic problem instead related to a chronic painful disease

With a long history of misunderstanding, poor society, provider education, and inconsistent laws, the prescription of opioids has resulted in significant societal challenges that will only resolve with significant education and training."

As 2024 begins, the ILPMP Peer Review Committee is working diligently with identified prescribers who meet the current threshold. While we understand there may be clinical circumstances warranting these prescribing patterns, we reach out to all identified prescribers for additional contextual clarification regarding their prescribing practices and provide education or academic detailing on risk mitigation strategies. Our partners at The University of Illinois Chicago College of Pharmacy provide this educational outreach on behalf of the ILPMP Peer Review Committee. For more information, see ILPMP.org **About Us** 

**Click to Read Article** 

Help Us Learn More About the State of Naloxone Distribution in Illinois and How We Can Better Support You and Your Community!


### **Attention Pharmacists & Pharmacy Technicians:**

**Pharmacists** and **pharmacy technicians** are encouraged to participate in a research study that is being conducted by the Cook County Department of Public Health (CCDPH) in partnership with the Illinois Department of Human Services (IDHS), Illinois Prescription Monitoring Program (ILPMP). In lieu of the **Illinois Naloxone Standing Order** (Public Act 099-0480), the goal of the study is to better understand naloxone knowledge, attitudes, and practices among pharmacists and pharmacy technicians in the state of Illinois.

By completing the survey, you are providing support on how to better serve pharmacists and pharmacy technicians in the distribution of naloxone to patients. This 15-minute survey is anonymous and conducted on the Qualtrics platform.

If you have any questions about the study, you may contact **Monica Chen at monica.chen@cookcountyhealth.org.** 





Cook County Department of Public Health is conducting a survey on pharmacist and pharmacy technician naloxone knowledge, attitudes, and practices. Please help us better support you and your communities by taking a <u>15-minute survey</u>.

#### **Eligibility:**


- Currently a registered pharmacist or registered pharmacist technician in the state of Illinois
- Currently practicing in the state of Illinois

## **Educational Resources**


### **NEW Webinar: Continuing Medical Education**

### **Benefits of a Designee**

- Describe the ILPMP program and registration process
- Explain how a prescriber can assign a designee



opportunity providing 1 hour of continuing education for **pharmacists** and **pharmacy technicians**. This continuing education









## **FREE Opioid Analgesic REMS CE**

#### **15-20 Minute Educational Outreach in a Virtual Visit**

Clinical pharmacists from UIC College of Pharmacy provide one-on-one interactive education on safely managing chronic pain.



### **Register Now!**




#### Learn more about:

- CDC Guideline Overview
- Opioid Alternatives
- · Opioid Use Disorder and Tapering Opioids
- Neonatal Opioid Withdrawal Syndrome
- · Saving Lives with Naloxone
- Prescription Drug Monitoring Program
- Opioid Storage and Disposal
- · Pain and OUD in Special Populations


# Each visit is approved for 0.5 hours of CME/CNE/CPE and meets DEA requirements for Opioid Analgesic education.

For more information, visit https://academicdetail.pharmacy.uic.edu/



Migraine Pharmacology:	Prophylaxis (PrEP)		Opioid Use Disorder (OUD): Harm Reduction	
Acute and Preventive Therapies		Obesity Medication		Strategies and Medications for OUD Update
Take a Breath: Asthma Medication Update in Pediatrics and Adult Car		Drug Prescribing in Pediatrics & Older Adults		Diabetes Medications: Orals and Injectables: What to Use & What will insurance pay for?
7.0 CE credits to attendees (7.0 pharmacology)	ISAPN Members - \$169 Non-Members - \$249 Pre Licensed APRN Student Member - \$109 <b>register at https://bit.ly/2024Pharm</b>			

## **ILPMP.ORG & PMPnow Monthly Data**



# **Contact Information**

If you have questions about the information that appears in this update or suggestions for future content, please email **dhs.pmp@illinois.gov**. Visit **www.ilpmp.org** for more information.





The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North Fourth Street, Springfield, IL 62702 www.ilpmp.org

Unsubscribe brittany.queen2@illinois.gov

Update Profile |Constant Contact Data Notice

Sent bydhs.pmp@illinois.govpowered by

